The efficacy of anti-programmed death ligand 1 (PD-L1)/programmed cell death 1 (PD-1)-targeted therapy has been well recognized in some types of cancer, including non-small cell lung cancer and malignant melanoma [11,12]. The gene discussed is PDCD1; the disease is cancer.